Kindeva Drug Delivery

Kindeva Drug Delivery is a purpose-fueled drug delivery contract development and manufacturing organization (CDMO) that leverages specialist injectable, inhalation and dermal expertise to accelerate clients' product journeys from development to commercial manufacturing. The company describes over a century of experience in drug delivery innovation, evolving from a drug-device manufacturer to a full-service CDMO, and reports state-of-the-art facilities in the U.S. and U.K. Its Bridgeton facility has over 155,000 sq. ft. of dedicated aseptic operations space, including laboratories, formulation suites and almost 11,000 sq. ft. of fill suites.

Kindeva Drug Delivery describes itself as having over a century of experience in drug delivery innovation, evolving from a drug-device manufacturer to a full-service contract development and manufacturing organization (CDMO). Since 1956, the company has been developing drug delivery technologies. Its milestones include creating the TruJect™ platform in 2009, which introduced a next generation of single-chamber autoinjectors; developing the first commercially available dose counter in 2010; inventing the CFC-free nasal MDI in 2012; and in 2024 developing low-GWP inhalers and planning the opening of one of the first commercial-scale green propellant lines for filling inhalers using propellants with up to 99.9% lower GWP than current options. The company reports approximately 1,300 patents, 10+ manufacturing and R&D facilities, 75 inventions in use, ~1M ft2 cGMP footprint, ~100M commercial devices shipped annually, and 2,000+ employees.

A leading global drug-device combination product CDMO with over a century of experience, offering tailored services across every stage of development and manufacturing.

• TruJect™ platform

  Next generation of easy and reliable single-chamber autoinjectors, widely used to deliver a variety of medications.

• CFC-free nasal MDI

  A more environmentally sound device for drug delivery capable of bypassing the blood-brain barrier.

• Dose counter

  First commercially available dose counter, ensuring patients knew the number of inhaler actuations remaining.

• Low-GWP inhalers

  Inhalers using propellants with up to 99.9% lower GWP than current options.

• Microneedle array patch

  Solid microneedle array patch development for accurate, reliable intradermal delivery.

1. 1CDMO | Drug-Device Combination | Kindevakindevadd.com
2. 2Kindeva History | Our CDMO Storykindevadd.com
3. 3Explore our expansive CDMO capabilities in our corporate brochure - Kindevakindevadd.com
4. 4Global CDMO | Full Service CDMO | Kindevakindevadd.com